MSCs-derived secretome counteracts the effect of apoptosis inhibition by SARS-CoV-2 S protein on Calu-3 cells mediated lowered expression of PTGS2
iCell · 2024
DOI: 10.71373/ouva4541 ↗Kurz gefasst
Fachartikel in der Zeitschrift iCell, 2024. Verfasst von Shuo Gao und 3 weiteren Autor:innen.
Abstract (Originalsprache)
The spike glycoprotein of severe acute respiratory syndrome coronavirus 2 is essential for viral entry, but its direct impact on host cell fate remains incompletely defined. Here we report that purified recombinant spike protein alone significantly suppressed apoptosis in human lung epithelial Calu‑3 cells in a dose‑dependent manner, even under actinomycin D‑induced apoptotic stress. This anti‑apoptotic effect was effectively reversed by conditioned medium derived from interferon‑γ‑primed umbilical cord mesenchymal stem cells (MSC‑CM). To explore the underlying molecular changes, we performed whole‑transcriptome RNA sequencing and identified hundreds of differentially expressed mRNAs, long noncoding RNAs, and circular RNAs, with the vast majority of these transcripts functionally enriched in inflammatory responses and apoptotic pathways. Among the candidate molecules, prostaglandin‑endoperoxide synthase 2 (PTGS2) showed the most prominent upregulation upon spike protein stimulation, and its protein level was markedly reduced by MSC‑CM treatment, suggesting a possible involvement of PTGS2 in the antagonistic action of MSC‑CM against spike‑induced apoptosis resistance. To further assess its clinical relevance, we analyzed public transcriptomic datasets and found that PTGS2 was consistently upregulated in SARS‑CoV‑2‑infected pulmonary cells and in autopsied lung tissues from fatal COVID‑19 cases. Moreover, in a multi‑omics Long COVID cohort, PTGS2 remained persistently elevated and its expression inversely correlated with residual pulmonary function, indicating a potential link to chronic inflammatory sequelae. Collectively, our findings reveal a novel pro‑survival function of the spike protein and point to PTGS2 as a candidate molecule worthy of further functional investigation. MSC‑CM, by downregulating PTGS2 and reinstating apoptosis, may represent a cell‑free approach with potential relevance for both acute COVID‑19 and Long COVID, though direct causal relationships remain to be established through future mechanistic studies.
Zitieren
APA
Gao, S., Ge, Y., Wang, H., & Luo, Y. (2024). MSCs-derived secretome counteracts the effect of apoptosis inhibition by SARS-CoV-2 S protein on Calu-3 cells mediated lowered expression of PTGS2. iCell. https://doi.org/10.71373/ouva4541
Vancouver
Gao S, Ge Y, Wang H, Luo Y. MSCs-derived secretome counteracts the effect of apoptosis inhibition by SARS-CoV-2 S protein on Calu-3 cells mediated lowered expression of PTGS2. iCell. 2024. doi:10.71373/ouva4541
BibTeX
@article{Gao2024,
author = {Gao, Shuo and Ge, Yao and Wang, Haojia and Luo, Yang},
title = {MSCs-derived secretome counteracts the effect of apoptosis inhibition by SARS-CoV-2 S protein on Calu-3 cells mediated lowered expression of PTGS2},
journal = {iCell},
year = {2024},
doi = {10.71373/ouva4541}
}
EUVIMED